Shares of Ascendis Pharma A/S (ASND) were down more than 12% in extended trading on Tuesday, following disappointing results from the company’s phase 1 single ascending dose study of TransCon Treprostinil in healthy volunteers, which assessed the pharmacokinetics of the drug, as well as injection tolerability and safety parameters.